Incyte Corp (NASDAQ:INCY)

74.86
Delayed Data
As of Jan 14
 +1.23 / +1.67%
Today’s Change
61.91
Today|||52-Week Range
101.47
+1.99%
Year-to-Date
Dodge & Cox Global Stock Fund's 4th-Quarter Commentary
Jan 17 / GuruFocus News - Paid Partner Content
AbbVie's (ABBV) Rinvoq Gets FDA Nod for Atopic Dermatitis
Jan 17 / Zacks.com - Paid Partner Content
Dodge & Cox Stock Fund's 4th-Quarter Commentary
Jan 17 / GuruFocus News - Paid Partner Content
AbbVie (ABBV) Seeks Rinvoq Nod for Non-Radiographic AS
Jan 10 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close73.65
Today’s open73.48
Day’s range72.83 - 74.94
Volume1,580,839
Average volume (3 months)2,079,671
Market cap$16.5B
Data as of 4:00pm ET, 01/14/2022

Growth & Valuation

Earnings growth (last year)-165.21%
Earnings growth (this year)+288.76%
Earnings growth (next 5 years)+60.89%
Revenue growth (last year)+23.53%
P/E ratio30.9
Price/Sales7.11
Price/Book6.29

Competitors

 Today’s
change
Today’s
% change
ALNYAlnylam Pharmaceutic...+0.50+0.34%
VTRSViatris Inc+0.20+1.33%
CTLTCatalent Inc-1.74-1.58%
HZNPHorizon Therapeutics...+0.70+0.77%
Data as of 4:00pm ET, 01/14/2022

Financials

Next reporting dateFebruary 17, 2022
EPS forecast (this quarter)$0.58
Annual revenue (last year)$2.7B
Annual profit (last year)-$295.7M
Net profit margin-11.09%

Profile

Sector
Health Technology
Industry
Biotechnology
No executives to display
Corporate headquarters
Wilmington, Delaware

Forecasts